Symposium Speaker: Minoli Perera, PharmD, PhD

Dr. Perera is an Associate Professor in the Department of Pharmacology and Center for Pharmacogenomics at Northwestern University's Feinberg School of Medicine.  With expertise in pharmacokinetics, clinical pharmacology and human genetics, Dr. Perera focuses her research interests on pharmacogenomics in minority populations.  Examples of her work include identifying common genetic variants associated with warfarin dose and identifying genomic risk factors for venous thromboembolism, both in African Americans.  Dr. Perera anticipates that results from these and other multidisciplinary studies will allow the development of an economically sustainable program in clinical pharmacogenetics, including a consult service.  Overall, Dr. Perera's goal is to bring meaningful translation of pharmacogenetics research findings into clinical care, a goal very much consistent with precision medicine.

Recent Publications

  1. Lindley, KJ, Limdi, NA, Cavallari, LH, Perera, MA, Lenzini, P, Johnson, JA, Wu, AHB, Ridker, PM, King, CR, Eby, CS et al.. Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles. Clin Pharmacol Ther 2022; 111 (4): 950-955. PubMed PMID:35108398 .
  2. Saulsberry, L, Danahey, K, Middlestadt, M, O'Leary, KJ, Nutescu, EA, Chen, T, Lee, JC, Ruhnke, GW, George, D, House, L et al.. Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. J Pers Med 2021; 11 (12): . PubMed PMID:34945816 PubMed Central PMC8709436.
  3. Perera, DDBD, Perera, KML, Peiris, DC. A Novel In Silico Benchmarked Pipeline Capable of Complete Protein Analysis: A Possible Tool for Potential Drug Discovery. Biology (Basel) 2021; 10 (11): . PubMed PMID:34827106 PubMed Central PMC8615085.
  4. De, T, Zhang, H, Alarcon, C, Lec, B, Avitia, J, Smithberger, E, Chen, C, Horvath, M, Kwan, S, Young, M et al.. Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease. Pharmacogenet Genomics 2022; 32 (1): 1-9. PubMed PMID:34380996 PubMed Central PMC8578201.
  5. Garofano, K, Park, CS, Alarcon, C, Avitia, J, Barbour, A, Diemert, D, Fraser, CM, Friedman, PN, Horvath, A, Rashid, K et al.. Differences in the Platelet mRNA Landscape Portend Racial Disparities in Platelet Function and Suggest Novel Therapeutic Targets. Clin Pharmacol Ther 2021; 110 (3): 702-713. PubMed PMID:34255863 .
  6. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 2021; 600 (7889): 472-477. PubMed PMID:34237774 PubMed Central PMC8674144.
  7. Singh, A, Zhong, Y, Nahlawi, L, Park, CS, De, T, Alarcon, C, Perera, MA. Incorporation of DNA methylation into eQTL mapping in African Americans. Pac Symp Biocomput 2021; 26 : 244-255. PubMed PMID:33691021 PubMed Central PMC7958994.
  8. Zhong, Y, De, T, Alarcon, C, Park, CS, Lec, B, Perera, MA. Discovery of novel hepatocyte eQTLs in African Americans. PLoS Genet 2020; 16 (4): e1008662. PubMed PMID:32310939 PubMed Central PMC7192504.
  9. Agrawal, S, Heiss, MS, Fenter, RB, Abramova, TV, Perera, MA, Pacheco, JA, Smith, ME, Rasmussen-Torvik, LJ, George, AL Jr. Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics. Clin Transl Sci 2020; 13 (5): 941-949. PubMed PMID:32270628 PubMed Central PMC7485961.
  10. Nooruddin, M, Scherr, C, Friedman, P, Subrahmanyam, R, Banagan, J, Moreno, D, Sathyanarayanan, M, Nutescu, E, Jeyaram, T, Harris, M et al.. Why African Americans say "No": A Study of Pharmacogenomic Research Participation. Ethn Dis 2020; 30 (Suppl 1): 159-166. PubMed PMID:32269457 PubMed Central PMC7138442.
Search PubMed

Dr. Perera on Twitter

Dr. Perera on Twitter

11y saw me crying and asked if it was about Uvalde. “Yeah,” I said. “It’s really sad and I worry about y’all.” “It’s okay, Dad,” he said to me, “we train for this.” Fuck. I’m broken. He’s in sixth grade. A math nerd. A gamer. He’s not a goddamn Marine. He “trains” for *this?* Retweeted by Dr. Minoli Perera

He is the voice of my pain and anger. Why are we held hostage? twitter.com/warriors/statu…

Appealing a rejection decision Retweeted by Dr. Minoli Perera

Writing is 20% typing, 80% trying to think of a better way to articulate something that has already been articulated perfectly well by someone else. Retweeted by Dr. Minoli Perera

In academia we don't say "I hate you" we say "the committee decided" and I think that's beautiful Retweeted by Dr. Minoli Perera

This puppy totally feels me…given the world and the nation, just hanging on! twitter.com/buitengebieden…

Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care | JAMA Pediatrics | #CPIC_PGRN2022 from ⁦@John_H_McD⁩ and ⁦@GeneticBilljamanetwork.com/journals/jamap… Retweeted by Dr. Minoli Perera

“You wake up in Chicago, pull back the curtain and you KNOW where you are. You could be nowhere else. You are in a big, brash, muscular, broad shouldered motherf***in’ city.” - @bourdain (RIP) Retweeted by Dr. Minoli Perera

We continue to see this graph. But Native ancestry is not even represented on it! So few studies you can’t even be represented. #CPIC_PGRN2022 @ericawoodahl

test Twitter Media - We continue to see this graph. But Native ancestry is not even represented on it! So few studies you can’t even be represented. #CPIC_PGRN2022 @ericawoodahl https://t.co/sVE46RUpJH

Don’t miss the Day 3 #CPIC_PGRN2022 keynote talk Dr. @GeneticBill | Rapid Point-of-Care Genotyping to Avoid Aminoglycoside Induced Ototoxicity in Neonatal Intensive Care @PALOH_Study @OfficialUoM @John_H_McD Retweeted by Dr. Minoli Perera

@ACCOuNT_NU twitter.com/sony_tuteja/st…

Great summary of the CYP2C19 genotype-guided antiplatelet “escalation” and “de-escalation” strategies to optimize clinical outcomes @UNCPharmacy @cpicpgx #CPIC_PGRN2022 Retweeted by Dr. Minoli Perera

Given a black box warning and several trial showing risk in patient carrying CYP2C19 variants, is it ethical to continue to give these patients Clopidogrel? Clearly there is also a risk with “just give everyone Ticagrelor”. Great questions at #CPIC_PGRN2022

Clopidogrel PGx. Great overview by Craig Lee of all the different studies and study designs. Escalation for LOF carriers ⬇️ MACE events. Deescalation for non carriers, ⬇️ bleeding. #CPIC_PGRN2022

test Twitter Media - Clopidogrel PGx. Great overview by Craig Lee of all the different studies and study designs. Escalation for LOF carriers ⬇️ MACE events. Deescalation for non carriers, ⬇️ bleeding. #CPIC_PGRN2022 https://t.co/7ytT22EKMW

We are recruiting a #PGx pharmacist to join our team @PennPrecisMed @PennMedicine. I’ll be attending the #CPIC_PGRN2022 Please contact me if interested @pgrnhub @cpicpgx Retweeted by Dr. Minoli Perera

@pwburridge getting the functional genomics done for this important study. twitter.com/sony_tuteja/st…

Yadav Sapkota presents Results from first study of cardio toxicity in African ancestry pediatric cancer survivors #CPIC_PGRN2022 Retweeted by Dr. Minoli Perera

@ufdeanjohnson explains how ancestry can have a huge effect on warfarin dose requirements. Linkage equilibrium can vary enormously across ancestries! #CPIC_PGRN2022 Retweeted by Dr. Minoli Perera

The Perera Lab Website

Curriculum vitae